Colón has been a member of the board of directors since 2023. She brings over 25 years of experience in biopharma, genomics, healthcare and industrial biotechnology. Colón most recently served as President, CEO and Director of InCarda Therapeutics, Inc., where she led the company’s growth from seed stage to late-clinical stage and oversaw strategy, commercial planning and pipeline growth. Prior to InCarda, Colón served as a partner and senior advisor to New Science Ventures LLC, where she led and co-led several investments and provided strategic and operational guidance to multiple life science portfolio companies. Previously, among multiple other roles, Colón served as a Senior Vice President and President of the Industrial Products Division at Precigen, Inc., (formerly Intrexon Corporation) and in various leadership roles at Gilead Sciences, Inc., including Head of Clinical Operations, Head of Alliance Management, and Head of Commercial Strategic Planning. Colón currently serves as a member of the Boards of Directors of CareDx, Inc., (NASDAQ:CDNA); the Massachusetts Institute of Technology (MIT) Corporation (MIT’s Board of Trustees); and the Biotechnology Innovation Organization (BIO), and she serves as the Executive Chair of ProterixBio, Inc. Previously, she served on the boards of PerceptiMed, Inc.; Paradigm Diagnostics, Inc.; and Cocoon Biotech, Inc. Colón received her Ph.D. in chemical engineering from MIT, where she was an NSF Fellow, and earned a B.S. degree in chemical engineering from the University of Pennsylvania, where she was a Benjamin Franklin Scholar.